Physician profile
Henry David Bruton
NPI 1003853417
$1,374.60
in general payments reported to CMS, 2019-2025
15 companies · $83.72 in 2025
The $83.72 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.30 · 2020: $12.09 · 2021: $43.93 · 2022: $908 · 2023: $245 · 2024: $69.69 · 2025: $83.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.25 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $262.46 | 2021-2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $257.68 | 2022-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $234.45 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $169.94 | 2020-2023 | Nucala, Trelegy Ellipta |
| Amgen INC. | $107.53 | 2022-2023 | Tezspire |
| Baxter Healthcare | $77.85 | 2022 | |
| Insmed, INC. | $55.89 | 2024-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.78 | 2022-2023 | Ofev |
| Mylan Specialty L.P. | $30.44 | 2022 | |
| Abbvie INC. | $29.26 | 2022 | |
| Genzyme Corporation | $23.84 | 2022 | |
| Harmony Biosciences LLC | $22.03 | 2023 | Wakix |
| Teva Pharmaceuticals USA, INC. | $20.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.14 | 2022 | |
| Pfizer INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Bruton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.